Altimmune to Present at Upcoming Conferences

Rhea-AI Summary

Altimmune announced management presentations at two upcoming conferences. A fireside chat at the H.C. Wainwright Global Life Sciences Conference will take place on March 9, 2021, featuring CEO Vipin Garg and other executives. Additionally, Chief Medical Officer Dr. Scott Harris will present at the NASH-TAG Conference on March 13, 2021, discussing dual GLP-1 agonists for treating liver dysfunction in NASH. Webcast links for both events are available on Altimmune's website, providing further insights into their innovative pipeline.

GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright Global Life Sciences Conference, being held Mar 9-10, 2021. Also, Altimmune’s Chief Medical Officer, Dr. Scott Harris, will be giving an oral presentation at the 2021 NASH-TAG Conference, being held March 11-13, 2021.

Details on the H.C. Wainwright fireside chat presentation are as follows:

Title:	H.C. Wainwright Global Life Sciences Conference
Presenters:	Vipin Garg, Ph.D., Chief Executive Officer Scot Roberts, Ph.D., Chief Scientific Officer Scott Harris, M.D., Chief Medical Officer
Date/Time:	March 9, 2021 at 7:00 am ET

A webcast link to the H.C. Wainwright fireside chat presentation will be accessible on the Events section of the Altimmune website.

Details on the NASH-TAG 2021 presentation by Dr. Scott Harris are as follows:

Title:	Dual GLP-1 Agonists in the Treatment of Metabolic & Liver Dysfunction in NASH
Presenter:	Scott Harris M.D., Chief Medical Officer
Date/Time:	March 13, 2021 at 9:30 pm ET

A copy of the presentation materials will be accessible on the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Investor & Media Contacts:

Will Brown	Stacey Jurchison
Chief Financial Officer	Sr. Dir, Investor Relations
Phone: 240-654-1450	Phone : 410-474-8200
wbrown@altimmune.com	sjurchison@altimmune.com

FAQ

What is the date of Altimmune's fireside chat at the H.C. Wainwright Conference?

Altimmune's fireside chat at the H.C. Wainwright Global Life Sciences Conference is scheduled for March 9, 2021, at 7:00 am ET.

Who will present at the NASH-TAG Conference for Altimmune?

Dr. Scott Harris, Chief Medical Officer, will present at the NASH-TAG Conference on March 13, 2021.

What topics will Altimmune discuss at the NASH-TAG Conference?

The topic of discussion will be 'Dual GLP-1 Agonists in the Treatment of Metabolic & Liver Dysfunction in NASH.'

Where can I find the webcast link for Altimmune's presentations?

The webcast links for Altimmune's presentations can be found in the Events section of their official website.

What is Altimmune's focus as a biopharmaceutical company?

Altimmune focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease.